Josef Zelinger - Jul 5, 2023 Form 4 Insider Report for Propanc Biopharma, Inc. (PPCB)

Role
Director
Signature
/s/ Josef Zelinger
Stock symbol
PPCB
Transactions as of
Jul 5, 2023
Transactions value $
$0
Form type
4
Date filed
8/23/2023, 04:05 PM
Previous filing
Aug 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PPCB Common Stock 2.81K Jul 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PPCB Common Stock Purchase Warrant Award $0 +15M $0.00 15M Jul 5, 2023 Common Stock 15M $0.01 By Aggro Investments Pty Ltd F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 1, 2023, the issuer effected a 1-for-1,000 reverse stock split (the "Reverse Split") of its outstanding shares of common stock, par value $0.001 per share ("Common Stock"). The number of shares of Common Stock reported on this Form 4 has been adjusted to reflect the Reverse Split as it pertained to the number of shares of Common Stock that the reporting person held immediately following the Reverse Split.
F2 The reporting person's Form 3 filed on August 20, 2021 inadvertently failed to report an additional 5 shares of Common Stock directly owned in error. Due to the method of rounding fractional shares of Common Stock held by the reporting person after the Reverse Split, the number of shares of Common Stock reported on this Form 4 has also been adjusted to correct the reporting person's total ownership as of August 23, 2023.
F3 Due to an administrative error, the reporting person inadvertently failed to report the beneficial ownership of the common stock purchase warrant (the "Warrant") issued to Aggro Investments Pty Ltd ("Aggro Investments") on July 5, 2023. The Warrant is currently exercisable, with shares of Common Stock issuable upon exercise subject to a 4.99% blocker based upon the aggregate number of shares of Common Stock outstanding on the date of such exercise. The reporting person wholly owns and controls Aggro Investments, but disclaims beneficial ownership of the Warrant and shares issuable pursuant to its exercise, except to the extent of the reporting person's pecuniary interest therein.
F4 Reflects the receipt of the Warrant for no additional consideration in connection with a loan from Aggro Investments to the issuer on July 5, 2023.